(1 - 8 von 21
)
Juventas and SironRX CEO Rahul Aras talks regenerative medicine
medcitynews.com
Regenerative medicine is the focus of two Cleveland Clinic spinoffs, Juventas and SironRX. Read an interview with the CEO of both companies, Rahul Aras.
The Alliance for Regenerative Medicine Names 32 Member...
www.wallstreet-online.de
Rahul Aras, President and CEO, Juventas Usman Azam, Global Head Cell & Gene Therapies Unit, Novartis Doug Doerfler, President & CEO, MaxCyte
Budding Entrepreneurs And Advocates Fear SEC Revision Could Cut Ranks...
www.ideastream.org
At issue is establishing what qualifies someone as an accredited investor.
Astellas makes another gene therapy play with Juventas dealwww.pmlive.com › pharma_news › astellas_makes_...
www.pmlive.com
· Jventas' Rahul Aras. Last year, researchers at INSERM in France showed that cell therapy with muscle-generating cells called myoblasts, ...
BioCardia and Juventas to start phase II trial for heart failure treatmentcardiovascularnews.com › News
cardiovascularnews.com
· ... I clinical trial and is an attractive delivery system for our targeted patient population,” said Rahul Aras, president and CEO Juventas.
Peripheral artery disease stem cell treatment gets new funds
medcitynews.com
Juventas, a regenerative medicine firm treating a form of peripheral artery disease, has money for trials. Read more about the stem cell treatment for ischemia.
sironrx gets third frontier funding for clinical trials, staff growthwww.freshwatercleveland.com › sironrx
www.freshwatercleveland.com
· ... product,” explains Rahul Aras, SironRX president and CEO. “With SRX100, we accelerate treatment in dermal wounds and prevent scarring.
sortiert nach Relevanz / Datum